Implications for Management
Use of FullTerm™, The Fetal Fibronectin Test, in conjunction with other clinical tests and information enables clinicians to better assess the overall risk of preterm delivery and to ensure appropriate patient management. In many cases, results of FullTerm, The Fetal Fibronectin Test, may help clinicians to avoid unnecessary interventions.
Considerations for patient management
The combination of fetal fibronectin testing and cervical length measurement allows you to determine the appropriate level of intervention for each patient.
Risk of Recurrent Preterm Birth (<35 Weeks)1
Patient and physician testimonials
References
- 1. Iams JD, Goldenberg RL, Mercer BM, et al. The preterm prediction study: recurrence risk of spontaneous preterm birth. Am J Obstet Gynecol. 1998;178:1035-40.
- 2. Peaceman AM, Andrews WW, Thorp JM, et al. Fetal fibronectin as predictor of preterm birth in patients with symptoms: A multicenter trial. Am J Obstet Gynecol. 1997;177:13-18.